IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CALDARA, ALESSIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 116
EU - Europa 107
NA - Nord America 72
SA - Sud America 11
AF - Africa 4
Totale 310
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 70
DE - Germania 63
SG - Singapore 56
CN - Cina 27
GB - Regno Unito 10
HK - Hong Kong 10
IT - Italia 7
IN - India 6
NL - Olanda 6
BR - Brasile 5
FR - Francia 5
RU - Federazione Russa 5
VN - Vietnam 5
ID - Indonesia 4
SE - Svezia 3
CI - Costa d'Avorio 2
CO - Colombia 2
EC - Ecuador 2
FI - Finlandia 2
IE - Irlanda 2
JP - Giappone 2
TR - Turchia 2
AR - Argentina 1
BB - Barbados 1
IQ - Iraq 1
JO - Giordania 1
KR - Corea 1
MA - Marocco 1
NO - Norvegia 1
PL - Polonia 1
PT - Portogallo 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UA - Ucraina 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 310
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 59
Singapore 25
Dallas 11
Ashburn 10
Beijing 9
Southend 9
Hong Kong 8
Santa Clara 7
Bengaluru 4
Hefei 4
Los Angeles 4
Munich 4
Boardman 3
Chandler 3
Abidjan 2
Council Bluffs 2
Dublin 2
Ho Chi Minh City 2
Istanbul 2
Jakarta 2
Moscow 2
New York 2
Princeton 2
Quito 2
San Francisco 2
São Paulo 2
Tokyo 2
Amman 1
Biên Hòa 1
Bridgetown 1
Buffalo 1
Candeias 1
Caracas 1
Columbus 1
Cota 1
Denver 1
Des Moines 1
Espoo 1
Ferraz de Vasconcelos 1
Guangzhou 1
Houston 1
Hyderabad 1
Jiaxing 1
Johannesburg 1
Juiz de Fora 1
Kropyvnytskyi 1
Lauterbourg 1
Libertad 1
Lisbon 1
Miami 1
Milan 1
Nanchang 1
Oslo 1
Port of Spain 1
Portsmouth 1
Pune 1
Quận Bình Thạnh 1
Rho 1
Salt Lake City 1
Shijiazhuang 1
Turku 1
Tây Ninh 1
Villavicencio 1
Warsaw 1
Wilmington 1
Xiamen 1
Yongin-si 1
Zakho 1
Totale 227
Salva come PNG Salva come JPEG
Nome #
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer 163
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 110
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer 29
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer 27
Totale 329
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.054
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.054
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 1 0 1 0 0 0 0
2021/20226 2 0 0 0 1 0 0 0 0 0 0 3
2022/202322 1 0 3 2 2 2 0 0 2 4 5 1
2023/202457 0 1 0 5 7 2 8 6 5 6 10 7
2024/2025102 7 17 6 12 12 3 0 5 3 9 4 24
2025/2026121 14 11 45 15 26 10 0 0 0 0 0 0
Totale 329